- Date of entry : 11/03/2026
- Associated laboratory(ies) : C3M Centre Méditerranéen de Médecine Moléculaire (INSERM-UCA) et ICN Institut de Chimie de Nice (CNRS-UCA)
- See the website
DimiCare is a pharmaceutical company developing a new generation of antimicrobials that are more specific and less prone to the emergence of resistance. It was founded through the collaboration of two research laboratories: the C3M (U1065, INSERM) in biology and the ICN (UMR 7272, CNRS) in chemistry.
Initiated in 2018, this collaboration led in 2022 to the identification of a new structural class showing strong activity against multidrug-resistant clinical strains and less resistance development. This work enabled the optimization of the compounds, the identification of a lead compound, and the creation of the entrepreneurial project DimiCare.
Supported by academic and institutional partners as well as Bpifrance, the project obtained the necessary proof of concept in 2025 to move toward the early-preclinical stage. In 2026, DimiCare Biotech is in the process of being established and aims to select a preclinical candidate in order to initiate the regulatory steps of its first development program between 2026 and 2027.
